scholarly journals Correlation between DVH parameters and lung function changes before and after radiotherapy and the occurrence of radiation-induced lung injury (RILI)

2021 ◽  
Keyword(s):  
Lung Function ◽  
Lung Injury ◽  
Before And After ◽  
Radiation Induced

Abstract The authors have requested that this preprint be withdrawn due to erroneous posting.

scholarly journals Correlation between DVH parameters and lung function changes before and after radiotherapy and the occurrence of radiation-induced lung injury (RILI)

2020 ◽  
Author(s):  
Sha Sha
Keyword(s):  
Radiation Therapy ◽  
Lung Function ◽  
Lung Injury ◽  
Univariate Analysis ◽  
Intensity Modulated Radiation Therapy ◽  
Related Factors ◽  
Logistic Analysis ◽  
Before And After ◽  
Radiation Induced ◽  
Diffusion Function

Abstract Background: The purpose of the study was to explore the correlation between DVH parameters and lung function changes before and after radiotherapy and the occurrence of radiation-induced lung injury (RILI), and to evaluate its value in predicting the risk of RILI.Methods: 120 patients with advanced non-small cell lung cancer who had been diagnosed in Jiaozhou Central Hospital of Qingdao City in the past three years and received chest conformal (intensity modulated) radiation therapy were selected. Before radiotherapy, irradiation of 45-50 Gy, and 1 month after the end of radiotherapy, the patients were tested for lung function, and the ventilation and diffusion function of the patients were tested using the Japanese CHESTAC-8800 lung function tester. The evaluation of radiation lung injury was based on the RTOG acute radiation lung injury classification standard, and the observation end point was ≥2 grade RILI.Results: A total of 34 patients with ≥2 grade RILI among 120 patients in this study, including 23 cases of grade 2 and 11 cases of grade 3, the incidence rate was 28.33%. The difference between FVC, FEV1, FEV1 / FVC, DLCO, V5, V10, V15 before radiotherapy, 45-50 Gy, and 1 month after the end of radiotherapy were statistically significant (P <0.05). Univariate analysis showed that lung function, V5, V10, and V15 before radiotherapy were related factors for RILI (P <0.05). Multivariate logistic analysis showed that the risk of RILI was 1.855 times that of patients with higher FEV1 / FVC before radiation therapy (OR = 1.855, 95% CI = 1.199-1.946, P = 0.037), patients with V10 ≥50% were 3.673 times higher than patients with V10 <50% (OR = 3.673, 95% CI = 1.548-7.582, P = 0.039).Conclusions: V10≥50% and FEV1 / FVC are high-risk factors for RILI before radiotherapy, which has certain value in predicting the risk of RILI.

scholarly journals Radiation Therapy Planning of Thoracic Tumors: A Review of Challenges Associated With Lung Toxicities and Potential Perspectives of Gallium-68 Lung PET/CT Imaging

2021 ◽  
Vol 8 ◽  
Author(s):  
François Lucia ◽  
Martin Rehn ◽  
Frédérique Blanc-Béguin ◽  
Pierre-Yves Le Roux
Keyword(s):  
Radiation Therapy ◽  
Lung Function ◽  
Lung Injury ◽  
Ct Imaging ◽  
Therapy Planning ◽  
Significant Treatment ◽  
Radiation Therapy Planning ◽  
Pet Ct ◽  
Thoracic Radiation ◽  
Radiation Induced

Despite the introduction of new radiotherapy techniques, such as intensity modulated radiation therapy or stereotactic body radiation therapy, radiation induced lung injury remains a significant treatment related adverse event of thoracic radiation therapy. Functional lung avoidance radiation therapy is an emerging concept in the treatment of lung disease to better preserve lung function and to reduce pulmonary toxicity. While conventional ventilation/perfusion (V/Q) lung scintigraphy is limited by a relatively low spatial and temporal resolution, the recent advent of 68Gallium V/Q lung PET/CT imaging offers a potential to increase the accuracy of lung functional mapping and to better tailor lung radiation therapy plans to the individual's lung function. Lung PET/CT imaging may also improve our understanding of radiation induced lung injury compared to the current anatomical based dose–volume constraints. In this review, recent advances in radiation therapy for the management of primary and secondary lung tumors and in V/Q PET/CT imaging for the assessment of functional lung volumes are reviewed. The new opportunities and challenges arising from the integration of V/Q PET/CT imaging in radiation therapy planning are also discussed.

scholarly journals P157 Potential benefit of intravenous immunoglobulin in connective tissue disease associated interstitial lung diseases

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Vasilis Kouranos ◽  
Lauren V Host ◽  
Corrado Campochiaro ◽  
Athol Wells ◽  
Christopher P Denton ◽  
...  
Keyword(s):  
Lung Function ◽  
Connective Tissue ◽  
Lung Diseases ◽  
Immunosuppressive Treatment ◽  
Interstitial Lung Diseases ◽  
Ivig Treatment ◽  
Before And After ◽  
Predicted Values ◽  
Relative Change ◽  
Median Change

Abstract Background/Aims  Intravenous immunoglobulin (IVIg) confers significant benefit in range of connective tissue diseases (CTD) including inflammatory myopathy (IM) of which interstitial lung diseases (ILD) are a major complication. This study aimed to assess the efficacy of IVIg on pulmonary involvement in refractory active CTD including systemic sclerosis (SSc). Methods  All patients with CTD-ILD confirmed on HRCT either with IM or SSc overlap myositis who did not achieve satisfactory clinical response to standard immunosuppressive agents and subsequently received regular IVIg infusions for IM were retrospectively identified. Serial lung function tests and immunosuppressive treatment regimen 9-12 months prior and 9-12 months after repeat courses of IVIg were recorded. Progressive ILD was considered when, despite immunosuppressive treatment, a relative FVC decline≥10% and/or relative DLco decline ≥15% were identified during the 9-12 months preceding IVIg treatment. The significance of median DLco and FVC percentage relative change to IVIg treatment was assessed by Wilcoxon signed-rank test. Results  22 patients (mean age 50.5±13.1 years old) with IM-ILD treated with IVIg were identified. ILD occurred in association with IM in 10 patients, overlap SSc myositis in another 11 patients, while one had mixed connective tissue disease with myositis. Lung function results were available for 19/22 (86%). Eight patients (42.1%) were found to have progressive ILD(four with IM and four with overlap SSc-myositis). The median change in FVC% predicted and DLco% predicted in the 9-12 months before and after IVIg treatment is presented in Table 1. There was a significant difference in the DLco% predicted rate of relative change before and after IVIg treatment (p = 0.035) for the overall cohort. However, no differences in lung function were observed in the rate of relative change between patients with IM and patients with SSc myositis overlap. Significant improvement in DLco% predicted values was identified in the subgroup analysis of patients with progressive ILD(p = 0.012). P157 Table 1:The median change in FVC and DLco% predicted values prior and after the IVIg treatmentPatients with myositis related ILD9-12 months before IVIg treatment (relative change)9-12 months after IVIg treatment (relative change)p-valueAll (n = 19)FVC % predicted-3.8 (-54.4 - 14.6)2.1 (-33 - 33.7)0.145DLco % predicted-9.2 (-60.7 - 9.2)-2.3 (-26 - 41.9)0.035PM/DM (n = 10)FVC % predicted-1.8 (-20.2 - 14.6)0.8 (-33 - 30.9)0.401DLco % predicted-9.6 (-60.7 - 9.2)-2.4 (-26 - 41.9)0.093SSc-PM/DM overlap (n = 11)FVC % predicted-6 (-54.4 - 10.6)3.4 (-19.9 - 33.7)0.139DLco % predicted-10.8 (-47.1 - 2.5)4.2 (-22.7 - 16.8)0.173Progressive ILD (n = 8)FVC % predicted-14.5 (-54.4 - 14.6)5.7 (-11.9 - 33.7)0.123DLco % predicted-25.3 (-60.6 - -14.1)12 (-2.3 - 41.9)0.012 Conclusion  IVIg may be an effective rescue therapy in the prevention of further lung function decline in refractory myositis and SSc overlap in particular in subgroups with progressive ILD. Future studies to determine its role in CTD-ILD are warranted. Disclosure  V. Kouranos: None. L.V. Host: None. C. Campochiaro: None. A. Wells: None. C.P. Denton: None. V.H. Ong: None. E. Renzoni: None.

Bronchoalveolar lavage and interstitial cells have different roles in radiation-induced lung injury

2003 ◽  
Vol 79 (3) ◽  
pp. 159-167 ◽  
Author(s):  
Ji-Hong Hong ◽  
Shih-Ming Jung ◽  
Thomas Chang Yao Tsao ◽  
Chi-Jung Wu ◽  
Chin-Yi Lee ◽  
...  
Keyword(s):  
Lung Injury ◽  
Bronchoalveolar Lavage ◽  
Interstitial Cells ◽  
Radiation Induced

scholarly journals Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma

2016 ◽  
Vol 48 (6) ◽  
pp. 1593-1601 ◽  
Author(s):  
Prathap Pillai ◽  
Yih-Chih Chan ◽  
Shih-Ying Wu ◽  
Line Ohm-Laursen ◽  
Clare Thomas ◽  
...  
Keyword(s):  
Mast Cells ◽  
Lung Function ◽  
Plasma Cells ◽  
Placebo Treatment ◽  
Forced Expiratory Volume ◽  
Atopic Asthma ◽  
Before And After ◽  
Bronchial Biopsies ◽  
Withdrawal Of Therapy ◽  
Therapy Reduction

Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE and inflammation and preserves/improves lung function when disease is destabilised by staged withdrawal of therapy.18 symptomatic, non-atopic asthmatics were randomised (1:1) to receive omalizumab or identical placebo treatment in addition to existing therapy for 20 weeks. Bronchial biopsies were collected before and after 12–14 weeks of treatment, then the patients destabilised by substantial, supervised reduction of their regular therapy. Primary outcome measures were changes in bronchial mucosal IgE+ cells at 12–14 weeks, prior to regular therapy reduction, and changes in lung function (forced expiratory volume in 1 s) after destabilisation at 20 weeks. Quality of life was also monitored.Omalizumab but not placebo therapy significantly reduced median total bronchial mucosal IgE+ cells (p<0.01) but did not significantly alter median total mast cells, plasma cells, B lymphocytes, eosinophils and plasmablasts, although the latter were difficult to enumerate, being distributed as disperse clusters. By 20 weeks, lung function declined in the placebo-treated patients but improved in the omalizumab treated patients, with significant differences in absolute (p=0.04) and % predicted forced expiratory volume in 1 s (p=0.015).Omalizumab therapy of non-atopic asthmatics reduces bronchial mucosal IgE+ mast cells and improves lung function despite withdrawal of conventional therapy.

ROLE OF RENIN-ANGIOTENSIN SYSTEM IN RADIATION-INDUCED LUNG INJURY

CHEST Journal ◽  
2008 ◽  
Vol 134 (4) ◽  
pp. 127P ◽  
Author(s):  
Rade Tomic ◽  
Elizabeth Jacobs ◽  
Metha Medhora ◽  
Andreea Antonescu-Turcu ◽  
Ghosh Swarajit
Keyword(s):  
Lung Injury ◽  
Renin Angiotensin System ◽  
Angiotensin System ◽  
Renin Angiotensin ◽  
Radiation Induced

scholarly journals AIRWAY PRESSURES DURING IPPV BEFORE AND AFTER LUNG INJURY

1989 ◽  
Vol 26 (5) ◽  
pp. 508-508
Author(s):  
Anders Jonzon ◽  
Torgny Norsted ◽  
Gunnar Sedin
Keyword(s):  
Lung Injury ◽  
Airway Pressures ◽  
Before And After
Sign in / Sign up

Export Citation Format

Share Document